AI Summary & Key Takeaways
AI InsightCONCLUSION The analyzes obtained suggest that survivin overexpression in CRC is associated with poor prognosis. (HR=1.446; 95% CI: 1.103-1.897).
📌 3 Key Takeaways
Abstract
OBJECTIVE Genome-level research qualifies survivin as the fourth-best “transcriptome” for colon, lung, brain, breast, and melanoma cancers. To date, it has been stated as a prognostic marker and therapeutic target in colorectal cancer (CRC). However, researchers on survivin expression in CRC are heterogeneous. Our current study aimed to reveal prognostic importance of survivin by investigating all CRC articles up to January 2021 that have performed analysis of survivin by immunohistochemical staining method. METHODS A comprehensive literature search for relevant studies published up to January 2021 was performed using SCOPUS and Pubmed databases. Only articles in which survivin was detected by IHC stain- ing were included in the study. All analyses were conducted by using Comprehensive Meta-Analysis. Eight articles and data of 1535 patients were included in the study. The Hazard Ratio was used to examine the relationship between CRC and survivin protein, for the relative weights of each research article. HR and 95% confidence interval values and general summary HR were calculated and forest plot graph was obtained. RESULTS Statistical heterogeneity Cochrane’s Q test statistics 24.156; p=0.004 and I2 value was obtained as 62,742. In line with the assumption that the data consisted of different populations, the HR and 95% CI values were calculated as 1.446 (1.103-1.897) using the Dersimonian and Laird random effects model. In order to evaluate the risk of publication bias, funnel plots were obtained, including log HR and standard error values on the x and y axes, respectively. CONCLUSION The analyzes obtained suggest that survivin overexpression in CRC is associated with poor prognosis. (HR=1.446; 95% CI: 1.103-1.897).